Study on the H l ne Nagy-Mignotte and colleagues at the University of Grenoble in France found that save lung cancer chemotherapy for recurr
Study on the H l ne Nagy-Mignotte and colleagues at the University of Grenoble in France found that save lung cancer chemotherapy for recurrent small cell (SCLC) may be invalid, which largely depends on the patient response to first-line chemotherapy. The study was published online July 16th in the Journal Cancer (Lung).
"We've known for a long time that there is only a 1 chance of a cure for SCLC," he said. If first-line treatment fails, consider the initial prognostic factors, as well as the timing and nature of response to first-line therapy."
The researchers analyzed data from 300 SCLC patients who received at least one line of chemotherapy. The patients were divided into three groups according to their response to first-line treatment, namely the sensitive group, the resistant group and the refractory group. "We are thus able to determine whether the prognostic factors for diagnosis are good or bad, and thus more likely to determine which patients are advised to do palliative care only to avoid ineffective treatment." At the end of first-line chemotherapy, 47.7% of patients were sensitive to the drug, and 24% were resistant, and the other 21.3% were refractory to treatment.
The results showed that the objective response rate was 73% lower than that of second-line chemotherapy at the time of first line chemotherapy, and was only 19.2% and 18.5% at the time of the three and four line chemotherapy, respectively. The complete response rate was 31.3% lower than that of the first line chemotherapy at the time of the three line chemotherapy (at the time of four line chemotherapy was about 0). The median survival time was shortened to 7.4 months after the first line chemotherapy, and after the first line chemotherapy for 5.1 months, the median survival time was only about four months after chemotherapy for the first three months, and the rate was only about 3.6 months after chemotherapy.
Based on the above results, the researchers concluded that the four line chemotherapy for patients with "sensitive" meaningless, "resistance" three line chemotherapy for patients with no significance, but the "refractory" patients need not receive second-line chemotherapy, except only a few patients selected by multidisciplinary consultation.
Dr. Rebecca Suk Heist of the Massachusetts General Hospital Cancer Center agrees with this conclusion. "Clinical trials should take into account the fact that SCLC patients have poor survival after chemotherapy and lack of effective therapy," he said. If a patient is seriously ill and can not receive standard chemotherapy or participate in clinical trials, he should be given the best supportive care and hospice care."
Article from http://www.iwarmyou.com/gcp/
Premature Ejaculation,Tumour,Hypertension,Depression,Tumour,Andrology Diseases,Tumour,Arthritis,Pain,Deaf,。 Cure999
Cure999 @ 2018